The New Advances in Cardioprotection

Dear Colleagues,

Cardiac disease remains the leading cause of death and disability worldwide. A number of molecular pathologic pathways, including excessive reactive oxygen species, calcium overload, inflammatory responses, cardiac fibrosis, apoptosis, cell death, and mitochondrial dysfunction, etc., have been identified, which induce cardiovascular risk factors, including ventricles hypertrophy, tissue ischemia, and arrhythmias, and result in sudden cardiac death and heart failure. Changes in patient demographics have meant that older and sicker patients with increasing co-morbidities, such as diabetes, left ventricular hypertrophy, renal failure etc., are undergoing coronary artery bypass graft surgery (CABG), often with concomitant valve and/or aortic surgery, thus increasing the risk of peri-operative myocardial injury and CABG-related myocardial infarction, and worsening clinical outcomes. As such, novel cardioprotective strategies are still required to attenuate the detrimental effects of acute myocardial ischemia and reperfusion injury, so as to prevent adverse LV remodeling, and reduce heart failure in patients with ischemic heart disease.  

This Special Issue of Healthcare seeks commentaries, original research, short reports, and reviews on recent advances in the field of cardioprotection with a focus on new drugs, targets, and approaches to treating cardiac ischemic/reperfusion injuries, and the use of mechanical devices in the treatment of heart failure, cardiogenic shock, or life-threatening arrhythmias. We would like to invite the authors’ views on the use of cardioprotective devices in patients undergoing percutaneous procedures and cardiac surgery. Additionally, we are looking for papers that can elucidate the cardioprotective effects of newer therapeutic measures in high-risk populations, such as those with diabetes, cancer, or multi-system disease.

Dr. Rahul Gupta
Dr. Akshay Goel
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Healthcare is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.